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ABSTRACT 1 
 2 
Context:  3 
Controversy exists regarding the therapeutic value of lymphadenectomy (LND) in 4 
patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer 5 
(MIBC). 6 
 7 
Objective:  8 
To systematically review relevant literature assessing the impact of LND on oncological 9 
and peri-operative outcomes in patients undergoing RC for MIBC. 10 
 11 
Evidence acquisition: 12 
MEDLINE, MEDLINE-in-Process, Embase, the Cochrane Central Register of 13 
Controlled Trials and LILACS were searched up to December 2013. Comparative 14 
studies reporting on no, limited, standard, extended, and super-extended LND, and 15 
oncological and peri-operative outcomes were included. Risk of bias and confounding 16 
assessments were performed.  17 
   18 
Evidence synthesis: 19 
23 studies reporting on 19,793 patients were included. All but one study were 20 
retrospective. Planned meta-analyses were not possible due to study heterogeneity 21 
therefore data were synthesized narratively. There were high risks of bias and 22 
confounding across most studies, and extreme heterogeneity in the definition of the 23 
anatomic boundaries of LND templates. All seven studies comparing LND with no 24 
LND favored LND in terms of better oncological outcomes. Seven of 14 studies 25 
comparing (super-)extended with limited or standard LND reported a beneficial 26 
outcome for (super-)extended LND in at least a subset of patients. No difference in 27 
outcome was reported in two studies comparing extended and super-extended LND. 28 
The comparative harms of different extents of LND remain unclear.  29 
 30 
Conclusions: 31 
Although the quality of the data was poor, the available evidence indicates that any kind 32 
of LND is advantageous over no LND. Similarly, extended LND appears to be superior 33 
to lesser degrees of dissection, while super-extended LND offered no additional 34 
benefits. Data from ongoing randomised clinical trials will hopefully clarify remaining 35 
uncertainties. 36 
 37 
Patient summary: 38 
The current literature suggests that removal of lymph nodes in bladder cancer surgery is 39 
beneficial and might result in better outcomes in terms of prolonging survival. 40 
However, the quality of the available studies is poor and high quality studies are 41 
needed. 42 
 43 
 44 
45 
1. INTRODUCTION 46 
Lymphadenectomy (LND) combined with radical cystectomy (RC) is considered the 47 
standard of care for patients with muscle-invasive bladder cancer (MIBC). Up to 25% of 48 
patients harbour lymph node (LN) metastases at the time of RC and the staging role of 49 
LND is unequivocal. In 1982, Skinner [1] was the first to report long term survival in 50 
LN positive patients undergoing RC and LND without systemic treatment. The 51 
therapeutic value of LND, however, remains a topic of continuous debate. Whilst the 52 
results of two ongoing randomised clinical trials (RCTs) evaluating the impact of 53 
different LND templates on survival are awaited, the current evidence base remains 54 
uncertain with regard to the true benefits and harms of LND. In this study we 55 
systematically reviewed the available literature to evaluate the impact of the extent of 56 
LND on survival and peri-operative outcomes in patients undergoing RC for MIBC.  57 
 58 
2. EVIDENCE ACQUISITION 59 
2.1  Search strategy 60 
The review was performed in accordance with the PRISMA statement and principles 61 
outlined in the Cochrane Handbook for Systematic Reviews of Interventions. [2,3] 62 
Highly sensitive electronic searches were conducted to identify all reports of RCTs or 63 
non-randomised comparative studies (NRCS) assessing LND in patients undergoing RC 64 
for MIBC. The searches were not limited by language or publication date. The 65 
databases searched were MEDLINE (1946 to December 2013), MEDLINE In-Process 66 
(December 20th 2013), Embase (1974 to December 2013), Cochrane Central Register 67 
of Controlled Trials (The Cochrane Library, Issue 8, 2013) and Latin American and 68 
Caribbean Center on Health Sciences Information (LILACS; December 2013). The 69 
database search was complemented by additional sources, including the reference lists 70 
of included studies which were hand searched, and additional reports identified by an 71 
expert panel (European Association of Urology (EAU) Working Group on MIBC). 72 
Ongoing trials were identified on clinicaltrials.gov. The full search strategy is presented 73 
in Appendix 1.   74 
Two reviewers independently screened titles and abstracts of all citations identified by 75 
the search strategies. Full text copies of all potentially relevant reports were obtained 76 
and independently assessed by the reviewers to determine whether they met the pre-77 
defined inclusion criteria. Any disagreements were resolved by consensus or arbitration 78 
by a third person. A data extraction form was developed specifically for the purpose of 79 
this assessment to collect information on study design, characteristics of participants, 80 
characteristics of interventions, and outcome measures.   81 
 82 
2.2 Inclusion and exclusion criteria  83 
The inclusion criterion was comparative studies only, and these included RCTs, 84 
prospective NRCS, prospective observational studies with a comparator arm, and 85 
retrospective comparative studies. Registry or database studies were also eligible, if the 86 
analysis was clearly structured as a comparison between control and intervention 87 
groups. Studies with no comparator group (e.g. single-arm case series), non-88 
effectiveness studies (e.g. nomogram studies), reviews, or studies with fewer than 10 89 
patients in each arm, were excluded. The study population was limited to patients with 90 
localized muscle-invasive urothelial or squamous cell carcinoma of the bladder (cT2-4 91 
N0M0). Studies including predominantly patients with variant histology other than 92 
squamous cell carcinoma were excluded because of its low incidence and the potentially 93 
different biological behavior of these cancers. Clinical staging was preferred, but if this 94 
was not reported, staging based on RC specimen was accepted. Studies with mixed 95 
populations (e.g. cTa, cTis, cT1) were retained for consideration for inclusion if there 96 
were no studies which included patients with MIBC exclusively. Studies including 97 
patients who underwent neo-adjuvant or adjuvant treatment were also retained. The 98 
types of interventions included LND undertaken during RC for bladder cancer. Due to 99 
the expected heterogeneity in defining the extent of LND across studies, the extent of 100 
LND was determined a priori based on discussion in an expert panel (EAU Working 101 
Group on MIBC) and were categorised as follows: (a) limited LND (or L-LND): LND 102 
confined to the obturator and/or peri-vesical fossa only; (b) standard LND (or S-LND): 103 
LND performed up to the common iliac arteries; (c) extended LND (or E-LND): LND 104 
performed up to the proximal boundary of the crossing of the common iliac vessels with 105 
the ureters or the aortic bifurcation, with or without the pre-sacral lymph nodes; and (d) 106 
super-extended LND (or SE-LND): LND performed up to the proximal boundary of the 107 
inferior mesenteric artery. The primary outcome was overall survival (OS); secondary 108 
outcomes included recurrence-free survival (RFS), disease-free survival (DFS), 109 
progression-free survival (PFS), cancer-specific survival (CSS) and peri-operative 110 
outcomes (e.g. operative time, blood loss, lymphocele). 111 
 112 
 113 
2.3 Assessment of risks of bias 114 
Two reviewers independently assessed the risk of bias (RoB) of individual studies. Any 115 
disagreement was resolved by discussion or reference to a third reviewer. The standard 116 
Cochrane Collaboration RoB tool [4] was used to assess the RoB in RCTs, whilst for 117 
NRCS, the RoB tool recommended by the Cochrane Non-Randomised Studies Methods 118 
Group was used. [5,6] In addition, for NRCS, the main confounders were identified a 119 
priori based on a study by Palmer et al. [7] In this study, a survey among bladder cancer 120 
experts was performed to identify and rank potential confounding variables and defining 121 
thresholds for imbalance for these variables. The main confounders identified are 122 
summarized in Table 1. Each confounder was assessed according to whether it had been 123 
considered by the authors, whether the confounder was balanced across the groups, and 124 
the degree to which adjustment had been made for the confounder. [7] The risk of 125 
confounding bias was considered to be high if the confounder was not 126 
described/considered, imbalanced between the groups or was not adjusted for in the 127 
statistical analysis. Review Manager 5.2 was used to present these results (Table 1). [8] 128 
 129 
2.4 Data analysis 130 
A narrative synthesis was performed. [9] Descriptive statistics were used to summarize 131 
baseline characteristics data. For continuous outcomes, data were summarized using 132 
mean (+/- standard deviation if available) and median (+/- interquartile range if 133 
available); for categorical outcomes, data were summarized using proportions. For 134 
summarizing outcome data, categorical outcomes were presented as proportions at 5 and 135 
10 year time points following surgery based on crude point estimates as reported by 136 
authors, with level of significance set at 5%. Outcomes at other time points were 137 
narratively described. For time-to-event data reported by authors using univariable or 138 
multivariable Cox regression analysis, data were summarized as hazard ratios (HRs) and 139 
95% confidence intervals (CIs).   140 
 141 
3. EVIDENCE SYNTHESIS 142 
3.1 Quantity of evidence identified and characteristics of included studies 143 
One thousand eight hundred and ninety-seven abstracts were identified by the search 144 
(Figure 1). Of these, 38 were selected for full text screening. One additional study was 145 
identified through reference searching. After full text screening, a total of 23 studies met 146 
the inclusion criteria. [10-32] Seven studies were reported only in the form of 147 
conference meeting abstracts, while 16 studies were reported in full-text papers. With 148 
one exception, all studies were retrospective comparative studies. Sixteen studies were 149 
single-centre studies, of which eight studies used a historical cohort as control group, 150 
and seven studies were multicentre studies.  151 
 152 
3.2 Risk of bias and confounding assessment of included studies 153 
Risk of bias (RoB) and confounding assessment for each of the individual studies were 154 
performed and the results are presented in Table 1. Due to the retrospective design in 22 155 
of 23 studies, there was high or unclear RoB across all domains. The issue of 156 
confounding was also poorly addressed by the majority of studies, as it was unclear in 157 
most studies if any of the confounding factors had been considered, either 158 
prospectively, or retrospectively through statistical adjustment. 159 
 160 
3.3 Results of comparisons of interventions 161 
 162 
3.3.1 No LND vs LND 163 
3.3.1.1 Baseline characteristics  164 
A total of seven studies comparing LND with no LND were identified, including a total 165 
of 13,833 patients (Table 2a). [10-16] The intervention differed between the studies and 166 
included any LND [10,14,15], L-LND [13], S-LND [11,12,16], E-LND [16] or SE-167 
LND [16]. 168 
 169 
3.3.1.2 Oncological outcomes 170 
Table 2b summarizes the oncological outcomes comparing no LND vs any LND. All 171 
studies reported a benefit for LND in at least one oncological outcome. Liu et al. [10] 172 
did not report any numerical data but stated that LND was associated with improved OS  173 
and DFS in pT1 patients only compared with no LND.  174 
 175 
3.3.1.3 Peri-operative outcomes 176 
No studies reported on these outcomes. 177 
 178 
3.3.2 Limited LND vs standard LND 179 
No studies were identified for this comparison. 180 
 181 
3.3.3 Limited LND vs (super-)extended LND 182 
3.3.3.1 Baseline characteristics 183 
Five studies addressed this question involving a total of 1,394 patients (Table 3a). [17-184 
21] Brossner et al. [21] focused on peri-operative outcomes. Bostrom et al. [19] 185 
compared L-LND with E-LND, however, an unknown number of patients in the E-LND 186 
group underwent SE-LND and over 50% of patients in the L-LND group did not 187 
undergo LND at all.  188 
 189 
3.3.3.2 Oncological outcomes 190 
Table 3b summarizes the oncological outcomes comparing L-LND with E/SE-LND. Of 191 
the five studies inluded, three studies reported improvement of at least one oncological 192 
outcome for E/SE-LND. [18-20] Brossner et al. [21] did not report oncological 193 
outcomes, while Hori et al. [17] found no statistically significant difference in 194 
oncological outcomes for L-LND and E-LND performing univariable analysis. 195 
 196 
3.3.3.3 Peri-operative outcomes  197 
Jensen et al. [20] reported no prolonged operative time for E-LND compared with L-198 
LND (mean 306 vs 302 minutes, p = 0.92). Brossner et al. [21], however, reported 199 
prolonged operative time for SE-LND compared with L-LND (median 330 vs 277 200 
minutes, p < 0.01). No differences in number of blood units transfused (1.15 vs 0.38 201 
respectively, p = 0.37), lymphoceles (none in both groups), 30-day complication rate 202 
(11% vs 9% respectively, p=0.28), and 30-day mortality (3 vs 1 event respectively, p = 203 
0.57) were reported in this study. [21] 204 
 205 
3.3.4  Standard LND vs (super-)extended LND 206 
3.3.4.1 Baseline characteristics 207 
Nine studies were identified involving 3,104 patients (Table 4a). [22-30] Four studies 208 
used data from the Cleveland Clinic. [22, 23, 25,28] Abd El Latif [23] differed from 209 
their previous study [22] by extending the study period by 2 years (2004-2010 vs 2006-210 
2010). One study specifically looked at the outcomes of laparoscopic LND. [25] 211 
 212 
3.3.4.2 Oncological outcomes 213 
Table 4b summarizes the oncological outcomes comparing S-LND with E/SE-LND and 214 
contradicting results were reported. Four studies noted no difference in oncological 215 
outcomes between S-LND and E-LND [22-24,30], although only one study on data 216 
from multivariable analysis. [22] Three studies reported a benefit for E-LND and one 217 
study reported a benefit for SE-LND for at least one oncological outcome. Subgroup 218 
analysis in these studies revealed no consistent subgroup that benefited most from E-219 
LND. For example, Poulsen et al. [26] reported a RFS benefit for E-LND in patients 220 
with organ-confined disease, while Dhar et al. [28] only found a RFS benefit for 221 
patients with >pT2 disease.   222 
 223 
3.3.4.3 Peri-operative outcomes 224 
Poulsen et al. [26] reported a lymphocele rate of 1.6% for E-LND and 1.5% for S-LND. 225 
One patient (0.8%) in the E-LND group died peri-operatively from complications 226 
unrelated to LND. Finelli et al. [25], performing laparoscopic LND, reported an 227 
estimated increase in operative time from 30-45 minutes for S-LND to 90 minutes for 228 
E-LND (no p-value reported).   229 
 230 
3.3.5 Extended LND vs super-extended LND 231 
3.3.5.1 Baseline characteristics 232 
Two multi-institutional studies, involving 1,462 patients were included. (Table 5a) 233 
[31,32] 234 
 235 
3.3.5.2  Oncological outcomes 236 
Table 5b summarizes the oncological outcomes comparing E-LND with SE-LND. Both 237 
studies reported no statistically significant difference in survival outcomes between E-238 
LND and SE-LND, irrespective of tumor stage or nodal status.  239 
 240 
3.3.5.3 Peri-operative outcomes  241 
No studies reporting on these outcomes were identified.  242 
 243 
3.4 Discussion 244 
3.4.1 Principal findings 245 
To the best of our knowledge, this study represents the most robust literature review 246 
focusing on the impact of  the anatomical extent of LND on post-RC oncological and 247 
peri-operative outcomes. The findings of this study suggest that any extent of LND is 248 
better than no LND for patients undergoing RC for MIBC, in terms of oncological 249 
outcomes. Additionally, E-LND might improve oncological outcomes compared with 250 
lesser degrees of dissection, although extending the dissection beyond E-LND is 251 
unlikely to yield any further benefits. With respect to peri-operative outcomes, a 252 
secondary outcome of this study, SE-LND resulted in increased operative time 253 
compared with less extended LND templates, but does not appear to substantially 254 
increase post-operative morbidity. 255 
 256 
3.4.2 Clinical implications of our study findings 257 
The data in this study support the routine performance of LND in patients undergoing 258 
RC. Whether the reported beneficial oncological outcomes are a result of stage 259 
migration (the so-called Will-Rogers Phenomenon), a true therapeutic benefit of LND, 260 
or a combination of both, remains uncertain. There is, however, a clear staging role of 261 
LND as supported by LN mapping studies [33, 34]. Thus, in spite of the lack of RCTs, 262 
the current evidence base is sufficiently convincing to recommend LND for patients 263 
undergoing RC for MIBC. While limited LND may contribute to disease staging, 264 
performing LND outside the true pelvis (i.e. ≥S-LND) should be considered a potential 265 
therapeutic intervention as skip nodal lesions are rare, therefore unlikely contributing to 266 
disease staging [33,34]. To date, however, questions remain about the potential 267 
therapeutic value of LND and what extent of LND is the most efficacious. Based on the 268 
current data, consisting of retrospective studies with a significant risk of bias and 269 
confounding, the evidence base is not strong enough to provide firm recommendations 270 
regarding the most optimal extent of LND. Conversely, these studies are currently the 271 
best available evidence and fairly consistently report an oncological benefit for E-LND 272 
compared with less extended LND templates. In addition, E-LND appears not to 273 
increase peri-operative morbidity. Collectively, there is accumulating evidence that E-274 
LND may be beneficial for patients undergoing RC for MIBC and is therefore 275 
recommended in patients undergoing RC for MIBC.  276 
 277 
3.4.3 How does this systematic review compare with other recent reviews? 278 
To our knowledge, two systematic reviews on the importance of LND in bladder cancer 279 
have been published. [35,36] Fan et al. [36] performed a systematic review and meta-280 
analysis of studies comparing E-LND and non-extended LND and its impact on RFS. 281 
The authors concluded that E-LND was associated with improved RFS compared with 282 
non-extended LND. Subgroup analysis revealed that patients with ≥pT3 bladder cancer, 283 
independently of LN status, benefit from E-LND. Tilki et al. [35] performed a 284 
systematic review only and concluded that the extent of LND may influence DFS after 285 
RC, independently of LN status and pT stage.  286 
The outcomes of our present study are in line with these reviews. However, there are 287 
important methodological differences which deserve discussion. Tilki et al. [35] 288 
included studies using the LN count as a surrogate for the extent of LND. Although an 289 
association between LN count, the extent of LND or even post-RC outcomes have been 290 
suggested [37-39], using the LN count as a surrogate for the extent of LND has 291 
limitations as acknowledged by the authors. Differences in surgical technique, sample 292 
processing and pathologic assessment greatly influence the LN count and consequently 293 
affect reproducibility. [37,40,41] Furthermore, the LN count cannot adequately be 294 
determined intra-operatively whereas surgeons can adhere to anatomic templates, 295 
making studies comparing LND templates more clinically relevant. For these reasons, 296 
only studies describing anatomic templates for the extent of LND were included in our 297 
review. In addition, although Tilki et al. [35] described some studies comparing LND 298 
templates (references 26,28,29,32), an additional 19 studies were included in this study 299 
providing a more comprehensive overview of studies comparing different LND 300 
templates. 301 
The attempt by Fan et al. [36] to perform a meta-analysis is noteworthy. Yet, the results 302 
of this study should be interpreted with caution. Aside from the low quality studies 303 
included in the analysis with its associated bias, differences in the definition of the 304 
extent of LND were not adjusted for in this study. Reflecting the lack of consensus on 305 
what constitutes a limited, standard, and extended or super-extended LND, there was 306 
significant heterogeneity in the definition regarding the extent of LND across studies. 307 
To illustrate, Abol-Enein et al. [29] and Dhar et al. [28] were both classified as E-LND 308 
studies while the proximal boundaries were the inferior mesenteric artery and crossing 309 
of the ureter with the common iliac vessels, respectively. For this reason, we chose to 310 
define the LND templates a priori and, if necessary, re-classify accordingly if 311 
sufficiently large numbers of studies did not match our chosen definitions. Although the 312 
definitions chosen for each of the LND templates may not be universally accepted by all 313 
clinicians, it at least allows for a certain degree of standardisation, which enables a 314 
comparison of outcomes among different LND templates. 315 
  316 
3.4.4 Strengths and limitations of the review 317 
The strength of the current study is the comprehensive literature review evaluating the 318 
impact of the extent of LND on post-RC outcomes using a robust and transparent 319 
methodological approach based on Cochrane review principles, incorporating the 320 
assessment of RoB and confounding which are essential in any review involving non-321 
randomised studies. The search strategy was complemented by additional sources for 322 
potentially important articles, which included an expert panel (EAU Working Group on 323 
MIBC). The review was limited to comparative studies, in order to maintain at least 324 
moderate levels of evidence. Throughout the entire review process, peer review was 325 
obtained from the expert panel, which represents a reference group of international 326 
experts. This approach ensured a comprehensive review of the literature, whilst 327 
maintaining methodological rigour, and enabled the authors to put into clinical context 328 
the relevance and implication of the review findings.  329 
 330 
The major limitation of the review is the quality of included studies; except for one 331 
prospective study, all studies were retrospective, non-standardized comparative studies 332 
with high risks of bias and confounding. In particular selection bias may have 333 
affected clinical outcomes, for example, cases with apparent nodal disease intra-334 
operatively where no LND was performed or less extended LND than anticipated. 335 
This review highlights the lack of high quality and reliable evidence concerning the 336 
benefits and harms of LND during RC in terms of oncological and peri-operative 337 
outcomes. The results, on the other hand, are supported by the fact that these studies are 338 
fairly consistent in reporting an oncological benefit. Currently, two phase III RCTs, one 339 
in Germany and one initiated by the Southwest Oncology Group (SWOG S1011), 340 
evaluating the impact of different LND templates on survival are ongoing. The final 341 
results of these studies, which will take several years (personal communication), may 342 
provide a more definitive answer to some aspects of this important clinical question. 343 
Standardization of the LND templates and surgeon expertise, however, are of critical 344 
importance for the success of these trials. 345 
 346 
4. CONCLUSION 347 
This systematic review set out to determine the evidence base in regard with the 348 
comparative effectiveness of LND in patients undergoing RC for MIBC, in terms of 349 
oncological benefits and peri-operative outcomes. The findings reveal a lack of 350 
randomised studies, and an evidence base derived mainly from retrospective studies 351 
with significant risks of bias and confounding. Nevertheless, the data indicate that any 352 
form of LND produces more favorable oncological outcomes compared with no LND. 353 
There was no evidence that LND results in increased perioperative adverse events than 354 
no LND. In terms of how different extents of LND influence outcomes, the findings 355 
indicate that E-LND might be superior to lesser degrees of dissection from an 356 
oncological perspective; however, extending the dissection beyond this (e.g. SE-LND) 357 
is not beneficial. The results of ongoing RCTs will hopefully clarify the remaining 358 
uncertainties regarding the role of LND during RC for MIBC. 359 
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Take Home Message 
 
Current evidence suggests that extended LND might be superior to lesser degrees of 
dissection in terms of oncological outcomes with comparable peri-operative morbidity. 
However, high quality data from randomised clinical trials are needed to draw a firm 
conclusion.  
 
 
 
 
 
  
 
 
 
 
 
